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ABSTRACT  22 
It has long been known that Tissue Factor (TF) plays a role in blood coagulation and has a direct 23 
thrombotic action that is closely related to cardiovascular risk, but it is becoming increasingly 24 
clear that it has a much wider range of biological functions that range from inflammation to 25 
immunity. It is also involved in maintaining heart hemostasis and structure, and the observation 26 
that it is down-regulated in the myocardium of patients with dilated cardiomyopathy suggests that 27 
it influences cell-to-cell contact stability and contractility, and thus contributes to cardiac 28 
dysfunction. However, the molecular mechanisms underlying these coagulation-independent 29 
functions have not yet been fully elucidated.  30 
In order to analyse the influence of TF on the cardiomyocitic proteome, we used functional 31 
biochemical approaches incorporating label-free quantitative proteomics and gene silencing, and 32 
found that this provided a powerful means of identifying a new role for TF in regulating splicing 33 
machinery together with the expression of several proteins of the spliceosome, and mRNA 34 
metabolism with a considerable impact on cell viability.  35 
 36 
SIGNIFICANCE 37 
In this study, using quantitative proteomics and functional biochemical approaches, we define for 38 
the first time that, in addition to its primary role in blood coagulation, Tissue Factor also plays a 39 
novel role in regulating cell splicing machinery, with a relevant impact on cell survival. 40 
This new function may help to explain the wide range of biological activities of TF, and thus 41 
provide fruitful clues for developing new strategies for treating human diseases in which TF is 42 
dysregulated.  43 
 44 
 3 
 
INTRODUCTION 45 
Tissue factor (TF), a 47-kDa transmembrane cell-surface protein, is primarily known as the 46 
initiator of the coagulation cascade [1, 2] but it also has a wide variety of coagulation-47 
independent functions: it is required for embryonic blood vessel formation [3], plays a role in 48 
tumour metastasis [4], and is involved in the maintenance of heart hemostasis and structure [5]. 49 
Fibroblasts and cardiomyocytes of the heart constitutively express high levels of TF, which is 50 
located in the sarcolemma of cardiomyocytes and the intercalated discs of myocardium, where it 51 
co-localises with cytoskeletal and adhesion proteins such as desmin and vinculin [6]. 52 
Furthermore, actin-binding protein 280 has been identified as a ligand for the TF cytoplasmic 53 
domain by two-hybrid screening [7]. These findings of co-localisation and interactions with 54 
structural cardiac proteins has led to the hypothesis that TF may also play a non-hemostatic role 55 
in the heart by maintaining the structural integrity and function of cardiac muscle [6, 7]. 56 
Furthermore, the pattern of TF expression in cardiomyocytes during human and murine heart 57 
development indicates that TF may act as a morphogenic factor in the developing heart [8]. 58 
TF is down-regulated in the myocardium of patients with dilated cardiomyopathy (DCM). 59 
Myocardial specimens from DCM hearts show that it has an altered cell localisation, being 60 
redistributed from the Z-bands to the perinuclear cytosol [9]. This further suggests that decreased 61 
TF expression and change in localisation may affect contractility and cell-to-cell contact stability, 62 
thus contributing to cardiac dysfunction in patients with DCM [9].  63 
The in vitro and in vivo administration of lipopolysaccharide reduces TF mRNA and protein 64 
expression in cardiomyocytes, but not in lung, kidney or brain [6, 10, 11], which not only clearly 65 
demonstrates that TF is uniquely regulated in the heart, but also suggests that it has potentially 66 
unique functions in heart morphogenesis and the maintenance of cardiac muscle structure.  67 
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Recent studies of murine cardiomyocytes have demonstrated that the stably transfected full-68 
length and alternatively spliced form of TF lacking exon 5 (asTF) [12] have anti-apoptotic 69 
activity in cells exposed to TNF-α [13] as a result of increased Akt expression and 70 
phosphorylation and the up-regulation of the anti-apoptotic protein Bcl-xL. Finally, a study by 71 
Eisenreich et al. has shown that the overexpression of asTF in murine cardiomyocytic cells also 72 
increases the expression of the pro-angiogenic and pro-migratory factors, such as VEGF, FGF2, 73 
and Cyr61 [5].  74 
The mechanisms underlying this plethora of effects have not yet been fully elucidated. In order to 75 
analyse the influence of TF on the protein expression in cells, it is essential to use a global 76 
approach such as that provided by proteomic analyses, which allow protein clusters to be 77 
identified in a single experiment. We analysed for the first time the influence of TF knock-down 78 
on the proteome of cardiomyocytic cells by identifying, quantifying, and classifying the proteins 79 
directly or indirectly regulated by endogenously expressed TF, and found that combining gene 80 
silencing technology with proteomic analysis [14, 15] is a very promising means of identifying 81 
the molecular patterns in which the silenced gene might be involved. We therefore used the data-82 
independent analysis (DIA) mass spectrometry-based method, named LC/MS
E
 [16], for label-free 83 
quantitative proteomics in order to detect the changes in the expression profile of cardiomyocytes 84 
caused by the siRNA-mediated gene silencing of TF.  85 
 86 
MATERIAL AND METHODS 87 
Cell cultures 88 
The HL-1 cardiomyocytes, a kind gift of Prof. W.C. Claycomb, (LSU Health Sciences Center, 89 
New Orleans, LA, USA), were cultured in complete Claycomb medium supplemented with 10% 90 
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FCS (JRH Biosciences, Lenexa, KS, USA) and 100 µmol/L norepinephrine (Sigma-Aldrich, 91 
Milan, Italy) according to Prof. Claycomb's instructions [17]. 92 
The MDA-MB-231 human breast adenocarcinoma cells were purchased from ATCC (LGC 93 
Standards S.r.l., Milan, Italy), and cultured in complete DMEM supplemented with 10% FCS 94 
(Euroclone S.p.A., Milan, Italy). 95 
 96 
MTT assay 97 
The MTT assay was based on the protocol first described by Mosmann [18]. Briefly, after being 98 
treated with small interfering RNAs or LY 294002 (Sigma-Aldrich, Milan, Italy), the cells were 99 
incubated for 4 h at 37°C with 0.1 mg/mL of MTT, dissolved in serum-free medium. Washing 100 
with PBS was followed by the addition of DMSO (1 mL in a well of a six wells/plate) and gentle 101 
shaking for 5 min in order to ensure complete dissolution. Absorbance was recorded at 550 nm 102 
using the microplate spectrophotometer system (Mithras LB940, Berthold Technologies, Bad 103 
Wildbad, Germany).  104 
 105 
RNA interference and cell transfection 106 
Validated high-performance purity grade small interfering RNAs (siRNA) against TF were 107 
synthesised by Qiagen Inc. (Milan, Italy) using the HiPerformance siRNA design algorithm and a 108 
proprietary homology analysis tool. Control siRNA, with a nonsilencing oligonucleotide 109 
sequence that does not recognise any known homology to mammalian genes, was also generated 110 
as a negative control. The siRNAs were dissolved in an appropriate volume of sterile water (20 111 
µmol/L). The cells were transfected with siRNA at 70-80% confluence using the HiPerFect 112 
Transfection Reagent (Qiagen Inc, Milan, Italy). After 24 h, the transfection procedure was 113 
repeated before analysis. 114 
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 115 
Immunofluorescence analysis 116 
The cells were fixed with 2% w/v paraformaldehyde containing 0.2% v/v Triton X-100 for 10 117 
min at room temperature and, after washing with PBS, were treated with acetone at -20°C for 5 118 
min, and rinsed three times with PBS. The samples were first incubated with the anti-SRSF2 119 
antibody (Sigma-Aldrich, Milan, Italy), and then with the Alexa Fluor 488 goat anti-mouse IgG 120 
antibody (Molecular Probes, Life Technologies Italia, Monza, Italy); the nuclei were stained with 121 
DAPI (Sigma-Aldrich, Milan, Italy). The images were acquired using an LSM710 Zeiss confocal 122 
inverted microscope equipped with Ar/Kr and UV lasers, and Zeiss Zen 2008 software. 123 
 124 
In situ hybridisation 125 
The cells were prepared for fluorescence in situ hybridisation by means of fixation with 4% w/v 126 
paraformaldehyde at room temperature for 8 min. After washing with PBS, the cells were 127 
permeabilised with 0.5% v/v Triton X-100 on ice for 5 min, and rinsed with PBS. Hybridisation 128 
was carried out at 42°C in a solution containing 2X saline sodium citrate buffer (SSC), 25% v/v 129 
formamide, 1 mg/mL of tRNA, 10% w/v dextran sulfate, and 50 µg/mL oligo-dT probe labelled 130 
with Alexa 488 at the 3' end. After hybridisation, the cells were washed twice for 15 min in 2X 131 
SSC, and once with 0.5X SSC at 42°C, and then fixed with 4% w/v paraformaldehyde at room 132 
temperature for 8 min. After three washes in PBS, the images were acquired using an LSM710 133 
Zeiss confocal inverted microscope equipped with Ar/Kr and UV lasers, and Zeiss Zen 2008 134 
software. 135 
 136 
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Dual-reporter cell-based splicing assay 137 
HL-1 cells were transiently transfected with the pTN24 dual-reporter splicing construct, with or 138 
without the human pTra2-α construct, for 24 h using DreamFectTM Gold (OZ Biosciences, 139 
Marseille, France) as described by the manufacturer. The sequence of both plasmids have been 140 
previously described in detail [19]. The cells were subsequently treated with control siRNA and 141 
TF siRNA (Qiagen Inc., Milan, Italy) for 48 h. After silencing, the cells were lysed, and equal 142 
amounts of proteins for each condition were assayed for luciferase and β-galactosidase activity 143 
using the Dual-Light
®
 Assay System (Applied Biosystems, Foster City, CA, USA) according to 144 
the manufacturer’s instructions. The assay data are expressed as the relative ratio of luciferase 145 
and β-galactosidase activity. 146 
 147 
Nucleosome immunoassay 148 
The histone-complexed DNA fragments (mono- and oligonucleosomes) were quantified using a 149 
one-step sandwich immunoassay (Roche Diagnostics, Mannheim, Germany), according to the 150 
manufacturer’s instructions. The data are expressed as absorbance/mg of cell proteins as 151 
determined by the Bradford protein assay. 152 
 153 
Western blotting  154 
Cell monolayers were harvested in Laemmli buffer containing 1 mmol/L PMSF, 10 μg/mL aprotinin 155 
and 5 mmol/L benzamidine, and equal amounts of proteins were separated on 12% SDS-156 
polyacrylamide gel and transferred to nitrocellulose membranes as previously described [20]. The 157 
membranes were incubated with primary antibodies against phosphorylated and total ERK1/2 (Cell 158 
Signalling Technologies, Danvers, MA, USA), phosphorylated and total Akt (Cell Signalling 159 
Technologies, Danvers, MA, USA), HtrA2 (Cell Signalling Technologies, Danvers, MA, USA), 160 
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hnRNP L and hnRNP K (Abcam, Cambridge, UK), polypyrimidine tract-binding protein-associated-161 
splicing factor, PTB (Antibodies-online, Aachen, Germany), heterogeneous nuclear 162 
ribonucleoprotein A1 protein, hnRNP A1 (Cell Signalling Technologies, Danvers, MA, USA). The 163 
blots were subsequently incubated with goat anti-rabbit or goat anti-mouse horseradish peroxidase-164 
conjugated secondary antibody (Bio-Rad Laboratories, Milan, Italy), and the bands were visualised 165 
by means of enhanced chemiluminescence (GE Healthcare, Milan, Italy). The densitometric analysis 166 
was carried out using QuantityOne software (Bio-Rad Laboratories, Milan, Italy).  167 
 168 
RNA extraction and cDNA preparation 169 
Total cellular RNA was extracted using TRIzol Reagent (Invitrogen Life Techonologies, Milan, 170 
Italy) and reverse transcribed at 42°C for 50 min, and at 70°C for 15 min (Bio-Rad Laboratories, 171 
Milan, Italy). For 1 µg of total cellular RNA, we used 200 units of reverse transcriptase (RT; 172 
SuperScript II, Invitrogen, Life Technologies, Milan, Italy), 3 µg random hexamer primers, 1 173 
mmol/L dNTPs, and 40 units Rnase inhibitor.  174 
 175 
Real-time reverse transcription polymerase chain reaction (RT-PCR) 176 
Real-time quantitative PCR (qRT-PCR) was carried out to detect TF mRNA, with 18S rRNA being 177 
used for sample normalisation. The primer sequences were: human TF sense: 5´-178 
CCTTACCTGGAGACAAACCTCG-3’; human TF antisense: 5´-179 
CCGTTCATCTTCTACGGTCACA-3’; human 18S sense: 5´-CGGCTACCACATCCAAGGAA-3´; 180 
human 18S antisense: 5´-CCTGTATTGTTATTTTTCGTCACTACCT-3´; mouse 18S sense: 5´-181 
GTAACCCGTTGAACCCCATT-3´; mouse 18S antisense: 5´- CCATCCAATCGGTAGTAGCG-3´. 182 
The primer sequences used for mouse TF (QT00159789) came from Qiagen Inc. (Milan, Italy). A 183 
volume of 2.5 µL of cDNA was incubated in 25 µL IQ Supermix containing TF or 18S primers and 184 
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fluorescence dye SYBRGreen (Bio-Rad Laboratories, Milan, Italy). Real-time RT-PCR was carried 185 
out in triplicate for each sample using an iCycler optical system (Bio-Rad Laboratories, Milan, Italy) 186 
 187 
PCR assay for the analysis of full-length and alternatively spliced TF (asTF) 188 
After denaturation at 94°C for 2 min, 1 µg of total cellular RNA was amplified using the one-step  189 
Invitrogen SuperScript III kit and a GeneAmp 9700 thermal cycler (Applied Biosystems, Life 190 
Techonologies, Monza, Italy) for 40 cycles (94°C for 15 s, 30 s at an annealing temperature of 66°C, 191 
and then 68°C for 30 s), with a final extension at 68°C for 5 min using the following primers: mouse 192 
TF sense: 5´- ACGAGATCGTGAAGGATGT - 3´; mouse TF sense: 5´- 193 
GAGATATGGACAGGAGGATG - 3´(Invitrogen Life Techonologies, Milan, Italy). The amplified 194 
products were separated by means of electrophoresis on a 2% agarose gel. 195 
 196 
PCR assay for the analysis of apoptotic genes affected by alternative splicing 197 
The Bcl-xL/Bcl-xS, Survivin, and TNF-related apoptosis inducing ligand (TRAIL) isoforms were 198 
analysed by means of semi-quantitative RT-PCR. The RNA was treated with DNase I (Invitrogen, 199 
Life Techonologies, Milan, Italy) and then underwent RT-PCR as described above. The primer 200 
sequences were: human Bcl-x sense: 5´- GAGGCAGGCGACGAGTTTGAA-3’; human Bcl-x 201 
antisense: 5´- TGGGAGGGTAGAGTGGATGGT-3’; human survivin sense 5′-GCA TGG GTG 202 
CCC CGA CGT TG-3′; human survivin antisense: 5′-GCT CCG GCC AGA GGC CTC AA-3′ [21]; 203 
human TRAIL sense: 5′-GAA TCC CAT GGC TAT GAT GGA GGT CCA G-3′; human TRAIL 204 
antisense: 5′-GGA TTC GAG GAC CTC TTT CTC TCA CTA-3′ [22]; human Glyceraldehyde-3-205 
phosphate dehydrogenase (GAPDH) sense: 5′-ACG GAT TTG GTC GTA TTG GGC G-3′; human 206 
GAPDH antisense: 5′-CTC CTG GAA GAT GGT GAT GG-3′.  207 
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The amplification products were analysed by means of agarose gel electrophoresis using 2% w/v 208 
agarose gels and Gel Red (Società Italiana Chimici, Rome, Italy), and the bands were captured 209 
under UV illumination. QuantityOne software (version 4.5.2, Bio-Rad Laboratories, Milan, Italy) 210 
was used for image acquisition and densitometric analysis.  211 
 212 
Cell proliferation assay  213 
Cell proliferation was evaluated using the Cell proliferation ELISA, BrdU (Roche Diagnostic, 214 
Monza, Italy), in accordance with the manufacturer’s instructions. Briefly, the cells were grown 215 
in 96-well tissue-culture microplates, and labelled by the addition of BrdU for 4 h. During the 216 
labelling period, BrdU is incorporated in place of thymidine in the DNA of the cycling cells. 217 
After removing the labelling medium, the cells were fixed, and the DNA was denatured in one 218 
step by adding FixDenat buffer. After removing the buffer, the anti-BrdU-POD antibody was 219 
added (which binds to the BrdU incorporated into the newly synthesised cellular DNA). The 220 
immune complexes were detected by means of the subsequent substrate reaction. The reaction 221 
product was quantified by measuring light emission using a scanning multi-well luminometer 222 
(Mithras LB940, Berthold Technologies, Bad Wildbad, Germany). 223 
 224 
Label-free LC-MS
E
 analysis 225 
The cell pellets were dissolved in 25 mmol/L NH4HCO3 containing 0.1% RapiGest (Waters 226 
Corporation, Milford, MA, USA) and digested as previously described [23]. The tryptic peptides 227 
were separated by means of nanoscale LC using a nanoACQUITY system coupled to a SYNAPT-228 
MS, a hybrid Q-TOF mass spectrometer (Waters Corporation, Milford, MA, USA), for 229 
qualitative and quantitative multiplexed LC-MS
E
 analysis. The control siRNA- and TF siRNA-230 
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treated samples (0.5 μg) were mixed with 50 fmol yeast alcohol dehydrogenase (ADH) digest as 231 
an internal standard for molar amount estimation [16], and analysed as previously described [24]. 232 
The LC-MS
E
 data were processed and searched using ProteinLynx Global Server (PLGS) v 2.3 233 
(Waters Corporation, Milford, MA, USA). Ion detection, data clustering, and the normalisation of 234 
the data-independent LC-MS
E
 data have been previously explained in detail [23, 25, 26]. 235 
Quantification of differentially expressed proteins identified by LC-MS
E
 was performed by 236 
quantifying the peptides identified for each protein using the Expression
E
 algorithm in PLGS v 237 
2.3. The regulation likelihood uses the confidence of identification of each peptide as a 238 
quantification weighting mechanism, and is specifically designed for independently acquired LC-239 
MS data. The overall likelihood of regulation is calculated using the Bayesian statistics-based 240 
Quantify algorithm in PLGS v 2.3, and is expressed by the probability of up-regulation (P >1): if 241 
this is <0.05 (i.e. between 0 and 0.05), the likelihood of down-regulation is >95%; if it is >0.95 242 
(i.e., between 0.95 and 1) the likelihood of up-regulation is >95% [23]. 243 
The significance of the regulation level was determined at a 20% fold change, but only proteins 244 
identified with at least 2 peptides with similar intensities in the technical replicates (CV<10%) 245 
were considered. The entire data set of differentially expressed proteins was further filtered by 246 
considering only the identifications from data with identified peptides that replicated at least two 247 
out of three technical instrument replicates and in two out of three biological replicates.  248 
 249 
2-dimensional electrophoresis (2-DE) and protein identification  250 
The cell pellets were dissolved in urea buffer (8 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 0.8% 251 
carrier ampholytes, pH 3-10, 20 mmol/L Tris, 55 mmol/L DTT, and bromophenol blue), and 2-252 
DE was carried out in accordance with the manufacturer's protocol (Protean IEF cell, Bio-Rad 253 
Laboratories, Milan, Italy) as previously described [27]. 2-DE was performed with three 254 
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independent biological experiments of control and TF-silenced cells, analysing each sample in 255 
triplicate. Progenesis SameSpot software (v 4.0, NonLinear Dynamics, Newcastle upon Tyne, 256 
UK) was used for gel alignment, spot detection, spot quantification, and normalisation for total 257 
spot volume in each gel, and the data were statistically analysed using the incorporated statistical 258 
package [27]. Significant between-group differences for each protein were computed using 259 
Student's t test, considering a p value of <0.05 as statistically significant with a fold change cutoff 260 
of 1.5. The protein spots selected for mass spectrometry analysis by LC-MS
E
 were in-gel digested 261 
with trypsin as previously described [28].  262 
 263 
Data mining 264 
Cytoscape (v 2.7) and BiNGO plugin (v 2.3) were used to make gene ontology (GO) assignments 265 
and determine the cell component and biological process GO categories that were significantly 266 
under- and over-represented, as previously described [23]. Statistical significance was determined 267 
by means of hypergeometric analysis followed by Benjamini and Hochberg’s false discovery rate 268 
correction (p<0.001) [29]. 269 
 270 
Statistical analysis 271 
The data are expressed as mean values ± SEM. The control and treated groups were statistically 272 
compared using Student’s t-test or ANOVA for repeated measures followed by Tukey's test. The 273 
accepted level of significance was p<0.05; n=the number of individual experiments performed in 274 
duplicate. 275 
 276 
RESULTS 277 
Effects of TF silencing on HL-1 cardiomyocytic cells. 278 
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The transfection of HL-1 cells with TF siRNA led to a 83.7±5.6% reduction in TF mRNA levels 279 
as evaluated by qRT-PCR (Figure 1A), and induced a greater decrease in cell viability in 280 
comparison with control cells. Specifically, the BrdU incorporation assay performed after TF 281 
silencing showed a significant decrease in the relative number of BrdU-positive cells (Figure 1B) 282 
accompanied by a remarkable inhibition of cell growth assessed by means of the MTT assay 283 
(Figure 1C). A nucleosome immunoassay used in order to investigate whether these effects were 284 
followed by an increase in apoptosis showed an increase in the apoptotic index after 16 h of up to 285 
2.2±0.3 times the control value (Figure 1D). 286 
 287 
Effects of TF silencing on the proteome of HL-1 cardiomyocytic cells. 288 
To analyse the effect of TF on the cardiomyocytic proteome further, we quantitatively compared 289 
the proteome of control and TF-silenced cells using a label-free LC-MS
E
 analysis of three 290 
independent biological replicates analysed in triplicate. Quality controls of the analysis showed a 291 
high mass precision, a retention time CV of <1%, and an intensity CV of <4.5%, which allowed 292 
an accurate comparison of the 370 proteins present in at least two out of three technical and 293 
biological replicates. The molecular weights, pI, PLGS scores, the mean number of unique 294 
identified peptides, sequence coverage, precursor RMS mass errors, and product RMS mass 295 
errors are reported in Supplementary Table 1 in [30]. 296 
After auto-normalisation, the intensities of accurate mass-retention time component clusters from 297 
control and TF-silenced cells were compared using PLGS v 2.3, as described in the Material and 298 
Methods section, thus providing a table of the relative fold change in the level of each identified 299 
protein. 300 
There were 33 non-redundant proteins that were differentially expressed under the two 301 
experimental conditions (Figure 2A); five were identified only in the control cell proteome, five 302 
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only in the TF-silenced cells, and 23 in both (nine down-regulated and 14 up-regulated in the TF-303 
silenced cells). 304 
Table 1 shows the proteins significantly up- or down-regulated in the control and TF-silenced 305 
cells, their scores, fold changes (expressed as log(e) of the ratio between the control and TF-306 
silenced cells), standard deviations, probabilities, and biological variations. 307 
The Biological Networks Gene Ontology (BiNGO) plugin was employed to search for the GO 308 
terms statistically over-represented among the differentially expressed proteins.[29] As shown in 309 
Supplementary Figure 1A, among the proteins that were down-regulated after TF-silencing or 310 
were unique in the control cells, the most over-represented GO terms in the biological process 311 
category were mRNA metabolic process and RNA splicing (for additional details see also 312 
Supplementary Table 2 in [30]). Furthermore, as shown in Supplementary Figure 1B, in the cell 313 
compartment category, the most over-represented GO term was the spliceosome, thus suggesting 314 
that TF silencing may principally alter the expression of proteins belonging to the spliceosome 315 
that are involved in mRNA processing and RNA splicing (for additional details see also 316 
Supplementary Table 2 in [30]). The down-regulation of polypyrimidine tract-binding protein-317 
associated-splicing factor (PTB), heterogeneous nuclear ribonucleoprotein A1 protein (hnRNP 318 
A1), and heterogeneous nuclear ribonucleoprotein L protein (hnRNP L) was further validated by 319 
immunoblotting (Figure 2B). 320 
We also used 2-DE analysis as a complementary approach to analyse the effect of TF silencing on 321 
the HL-1 proteome. Comparison of the 2-DE maps of the control and TF-silenced cells (Figure 322 
3A-B) revealed a statistically significant decrease in the expression of the heterogeneous nuclear 323 
ribonucleoprotein K protein, hnRNP K (Figure 3C), and a significant increase in the expression 324 
of the pro-apototic serine protease HtrA2 (Figure 3D), both of which were confirmed by means 325 
of immunoblotting (Figure 3E-F). Supplementary Table 1 shows the protein name, Uniprot 326 
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accession code, fold increase in the TF-silenced cells, p value, molecular weight, pI, protein 327 
score, percentage of coverage, precursors RMS error, and peptide sequences and scores of the 328 
differentially expressed proteins in the 2-DE gels. 329 
 330 
Effects of TF silencing on mRNA distribution and spliceosome morphology 331 
As splicing activity is required for efficient mRNA transport [31], we next examined whether TF 332 
silencing affects the subcellular distribution of mRNA. The in situ hybridisation of poly(A) RNA 333 
showed that large populations of mRNA species were distributed in the cytoplasm of the control 334 
cells, whereas, after cell treatment with TF siRNA, a lower cytoplasmic RNA signal was 335 
observed (Figure 4).  336 
We also investigated whether TF silencing affects the distribution of splicing factors such as 337 
SRSF2, which is known to be organised in a specific “speckled” distribution pattern in the 338 
nucleus. The sub-nuclear organisation of SRSF2-containing speckles was also greatly affected by 339 
TF silencing, with an increase in both size and content as measured by immunofluorescence 340 
(Figure 5). A similar effect was observed in cells in which SF3a (another U2 snRNP component) 341 
has been knocked down [32], or in cells treated with oligonucleotides that inhibit pre-mRNA 342 
splicing [33].  343 
 344 
Effects of TF silencing on pre-mRNA splicing activity 345 
In order to examine whether TF plays a role in pre-mRNA splicing in vivo, we used the dual-346 
reporter system described by Nasim et al. [19]. The reporter construct (pTN24) contains genes 347 
encoding β-galactosidase and luciferase proteins. The assay was constructed in such that in the 348 
absence of splicing, it gives rise to β-galactosidase, whereas an efficient splicing reaction 349 
generates the fusion of β-galactosidase and luciferase (Figure 6A). The splicing efficiency was 350 
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therefore measured as a relative ratio of luciferase and β-galactosidase activities. TF silencing 351 
significantly decreased splicing activity (Figure 6B). The co-transfection of pTN24 and pTra2-α, 352 
an established splicing activator [19], increased the luciferase/β-galactosidase ratio 1.6±0.2 times 353 
in comparison with the cells transfected with pTN24 alone (p<0.05) and, also under this 354 
condition, TF silencing significantly decreased splicing activity (Figure 6B). Overall, these 355 
findings indicate that TF acts as a spliceosome modulator, and that TF silencing inhibits mRNA 356 
splicing activity.  357 
 358 
TF silencing decreases cardiomyocytic cell viability by influencing the regulators of apoptosis 359 
The levels of the phosphorylated forms of Akt and Erk1/2 were examined in order to investigate 360 
which of the pathways that ultimately lead to cell apoptosis is affected by TF silencing. The level 361 
of phosphorylated Akt was lower in the TF-silenced cells than in the control cells (Figure 7A), 362 
whereas Erk1/2 levels were not affected (data not shown). Interestingly, Akt inhibition by LY 363 
294002 up-regulated the pro-apoptotic serine protease HtrA2, and concomitantly reduced cell 364 
growth (Figure 7B and 7C).  365 
Finally, semi-quantitative RT-PCR revealed an increase in the mRNA of the pro-apoptotic Bcl-xS  366 
isoform over the anti-apoptotic Bcl-xL transcripts following TF silencing in human MDA cells 367 
which, unlike murine cells, express detectable levels of Bcl-xS [34] (Figure 7D). The anti-368 
apoptotic Survivin and its splice variant, Survivin-DEx-3 were both downregulated in TF-369 
silenced cells (Figure 7E). The splice variant Survivin-2B, which shows a markedly reduced anti-370 
apoptotic potential, was not detectable in our experimental conditions. TNF-related apoptosis 371 
inducing ligand (TRAIL), detectable only as regularly spliced TRAILα, was not affected by TF-372 
silencing (Figure 7F). 373 
 374 
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DISCUSSIONS  375 
Our proteomic analysis revealed for the first time that TF silencing affects various proteins 376 
belonging to the spliceosomal complex [35] and, by modulating spliceosome proteins, inhibits 377 
splicing activity, as assessed by means of a dual-reporter mRNA splicing assay, and changes the 378 
normal speckled pattern of SRSF2 together with a decreased poly(A) RNA signal in the 379 
cytoplasm. The impaired splicing efficiency due to TF silencing was accompanied by a loss of 380 
cell survival, which was likely attributable to a decreased level of phosphorylated Akt, an 381 
increase in the Bcl-xS spliced isoform, a decrease of the anti-apoptotic wild-type Survivin and 382 
Survivin DEx-3 isoforms, and the induction of pro-apoptotic HtrA2 expression. Our results 383 
further confirm and extend previous findings by Boltzen et al. [13] showing that TF 384 
overexpression protects cardiomyocytes from apoptosis induced by TNF-α by activation of Akt 385 
and up-regulation of anti-apoptotic Bcl-xL.  386 
The dysregulation of splicing machinery caused by TF silencing is due to alterations in the 387 
expression of RNA helicases and splicing factors such as members of the hnRNP family. 388 
We found that the expression of DEAD box UAP56 helicase was down-regulated in TF-silenced 389 
cells. UAP56 is an important factor for spliceosome assembly, mRNA export and translation, and 390 
it plays an important role in cell growth and proliferation [36-38]. DDX39, a paralogue of 391 
UAP56 that is expressed in a growth-regulated manner [39, 40], was also down-regulated after 392 
TF silencing. Another member of the helicase family that was significantly down-regulated by 393 
the silencing of TF was DEAD box RNA helicases p72 (DDX17), which plays important roles in 394 
multiple cell processes, including transcription, processing of miRNAs and pre-mRNAs and 395 
alternative splicing [41]. 396 
Five members of the hnRNP family were down-regulated by TF silencing: hnRNP C, A1, D0, L, 397 
and K. HnRNP proteins are among the most abundant nuclear proteins (rivalling histones), 398 
 18 
 
participate in pre-mRNA processing activities such as splicing and are important determinants of 399 
mRNA export, localisation, translation and stability [42]. Given their central role in regulating 400 
gene expression, it is not surprising that hnRNPs have been linked to numerous diseases [43][44], 401 
ranging from cancer to neurodegenerative diseases [45, 46].  402 
Interestingly, hnRNP A1, which was significantly down-regulated in TF-silenced cells, plays a 403 
key role in the regulation of cell survival, promoting telomere length extension [47, 48]. More 404 
recently, Fujiya et al. demonstrated that either siRNA targeting of hnRNP A1 or 405 
autophagolysosomal degradation of hnRNP A1 induced by miR-18a lead to cell apoptosis [49]. 406 
One new finding is that TF silencing profoundly down-regulated the expression of matrin 3, a 407 
highly conserved inner nuclear matrix protein which, through a direct interaction with hnRNP 408 
proteins and with the DNA and RNA helicase DHX9, might control RNA metabolism and 409 
stabilisation [50].  410 
The proteomic analysis of TF-silenced cells also revealed that other spliceosome proteins were 411 
also significantly down-regulated, including SF3b (SAP130) and PTB. It is interesting to note 412 
that two natural products, pladienolide B and spliceostatin A, targeting the SF3b subunit of the 413 
spliceosome [51], provoke the accumulation of incompletely processed pre-mRNA, inhibit cell 414 
growth [52] and alter the size and number of snRNP-enriched nuclear speckles [32], similarly to 415 
the effects observed by Tanackovic et al., when specific splicing factors are inactivated [53]. 416 
PTB binds to uridine-rich sequences and regulates alternative splicing of a variety of pre-mRNAs 417 
[54], acting as a general repressor of exon inclusion. For example, PTB, binding to an exonic 418 
splicing silencer, promotes Fas exon 6 skipping and generates a soluble isoform that prevents 419 
apoptosis [55]. The finding that TF silencing down-regulates PTB protein level suggests that this 420 
splicing modulator is no longer operating. 421 
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TF silencing also increased the expression of the spliced isoform of the pro-apoptotic Bcl-xS. 422 
This is in line with the finding of Boltzen et al., who showed that Bcl-xL is an important factor 423 
mediating anti-apoptotic effects in HL-1 cells stably transfected with TF [13]. Bcl-X is closely 424 
related to Bcl-2 and exists in several isoforms generated by alternative splicing [56]. The large 425 
isoform, Bcl-xL, protects cells against apoptosis, whereas the short isoform Bcl-xS, antagonises 426 
the inhibition of cell death by interacting with Bcl-xL and Bcl-2 [56]. It is worth noting that 427 
alternative splicing can be regulated by hnRNP proteins binding exonic splicing silencer 428 
elements, thus excluding exons from mature mRNA. One study has found that hnRNP K may 429 
play a prominent role in alternative splicing control because nearly half of 56 alternative splicing 430 
events in apoptotic genes were affected upon hnRNP K depletion, either enhancing or 431 
suppressing exon inclusion [57]. In support of our finding, it has been shown that hnRNP K 432 
represses the production of the pro-apoptotic Bcl-xS spliced isoform, whereas its down-regulation 433 
enhances the splicing of Bcl-xL to Bcl-xS [58].  434 
We also found that the anti-apoptotic Survivin and its splice variant, Survivin-DEx-3, were both 435 
down-regulated by TF silencing. Survivin is a member of the inhibitor of apoptosis protein (IAP) 436 
family and plays an important role in inhibiting cell apoptosis [59]. In addition to wild-type 437 
Survivin, different isoforms characterised by distinct localisation and functions have been 438 
identified. For example, Survivin 2B has a pro-apoptotic function, whereas the nuclear Survivin 439 
DEx-3 isoform has typically been shown to prevent apoptosis [21]. Our finding is in line with 440 
previous results showing that TF-FVIIa-FXa complex prevents apoptosis by a thrombin-441 
independent pathway mediated in part by an increase in cell Survivin levels [60]. 442 
Although our analysis is limited to few candidates, the effect of TF silencing on apoptosis-related 443 
genes does not appear to be widespread because, for example, the TRAIL gene is not affected in 444 
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TF-silenced cells. TRAIL-α is a member of the TNF family [61] which induces programmed cell 445 
death in a wide range of neoplastic cells. 446 
The inability to detect, in our experimental system, the pro-apoptotic splice variant of Survivin, 447 
Survivin 2B, and the two alternative TRAIL-splice variants, TRAIL-β and TRAIL-γ, which are 448 
characterised by the loss of their pro-apoptotic properties [22], does not allow us to establish a 449 
clear relationship between TF-mediated deregulation of splicing factors and these proteins 450 
involved in the apoptotic process.  451 
As stated above, in addition to being the main initiator of the blood coagulation cascade, TF is 452 
also a true signalling receptor that acts by means of various mechanisms, including the activation 453 
of protease-activated receptors 1 and 2, via the TF cytoplasmic domain and the transactivation of 454 
receptor tyrosine kinases. The activation of signalling cascades such as the mitogen-activated 455 
protein kinase and phosphoinositide 3-kinase (PI3K)/Akt pathways relates TF to a multitude of 456 
cell functions, such as cell survival, migration, and proliferation [62, 63].  457 
It is worth noting that TF silencing significantly reduced phosphorylated Akt levels, whereas the 458 
levels of phosphorylated Erk1/2 were unaffected. Furthermore, Akt inhibition led to the induction 459 
of apoptosis because Akt is a serine/threonine kinase that, once activated by phosphorylation, 460 
plays an important role in regulating a number of cell processes that deliver an anti-apoptotic 461 
signal. Supporting the association between TF level and cell survival, cardiomyocytes stably 462 
transfected with TF show less TNFα-induced apoptosis and a higher degree of activation of the 463 
Akt pathway [13]. Moreover, anti-apoptotic Bcl-xL expression was increased in HL-1 cells 464 
overexpressing TF, thus underlining the positive association between TF, the Akt pathway and 465 
anti-apoptotic Bcl-xL. Interestingly, PI3K/Akt signaling pathway has been implicated to play an 466 
important role in the regulation of Survivin [64].  467 
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The nature of the interaction between signalling pathway and splicing machinery in TF-silenced 468 
cells was not elucidated in this study, but we can hypothesise that splicing factors may represent 469 
targets of the signaling molecules. A wide variety of interactions have been described between 470 
components of the RNA processing machinery and traditional signalling molecules: for example, 471 
hnRNP K protein contains multiple modules that bind kinases while recruiting chromatin, 472 
transcription, splicing and translation factors [65]. We focused our analysis to kinases such as the 473 
mitogen-activated protein kinase and PI3-kinase/Akt pathways because they are related TF 474 
signalling, and we have not analysed the full spectrum of kinases and phosphatases (reviewed in 475 
[66]) involved in the post-traslational modifications of the spliceosomal components and 476 
accessory splicing factors which significantly contribute to their activity. Regulation of splicing 477 
factors by Akt is not heretical [67]; activated Akt has been involved in directly modulating 478 
serine/arginine-rich proteins (SR proteins) [68]; more recently, hnRNP L has been recently 479 
identified as a direct substrate of Akt, thus influencing the alternative splicing of caspase-9 [69], 480 
and down-regulation of splicing factors has been also observed in U373 glioma cells after Akt 481 
silencing [70]. Furthermore, SR-specific protein kinases (SRPKs) are also directly regulated by 482 
Akt [71]; lastly, a phosphoproteomic screen of Akt isoforms identified 25 RNA processing 483 
proteins including splicing factors as Akt isoform-dependent targets [72].  484 
Our data also reveal for the first time that TF silencing up-regulates HtrA2 expression, and that 485 
blocking Akt signaling by means of the PI3K inhibitor LY294002 modulates HtrA2 in a similar 486 
manner, thus providing a further mechanism by which TF promotes cell survival through Akt.  487 
The serine protease HtrA2 leads to programmed cell death in both a caspase-dependent and 488 
caspase-independent manner. Its function closely relates to its protease activity, which is required 489 
for the cleavage of its substrates. However, the regulation of HtrA2 by a signalling molecule has 490 
not been previously documented. Yang et al. have demonstrated that the ectopic expression of 491 
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HtrA2 considerably induces programmed cell death, whereas apoptosis is largely reduced by 492 
constitutively active Akt [73].  493 
We recognise some limitations in our study. One limitation is the fact that we could not 494 
discriminate the relative contribution of full-length and alternatively spliced TF, which are both 495 
expressed in the cardiomyocytic cells although to different extents (full-length TF is the main 496 
isoform and accounts for 85±6% of expressed TF) (Supplementary Figure 2) and, although they 497 
have functionally different features, appear to be involved in similar biological processes [62].  498 
We evidenced a reorganization of SRSF2 in TF-silenced cells in which “speckles became larger, 499 
rounded and decreased in number with a concurrent increase in their fluorescent intensity” 500 
attributable to the “return of splicing factor to theirs site of storage and/or assembly, until splicing 501 
is resumed”, similarly to what observed by O’Keefe et al. [33]. However, a precise picture of the 502 
SR proteins involved in this phenomenon has not been depicted as the antibody used does not 503 
discriminate between SRSF2 and SRSF2-related non-snRNP factor SF2/ASF. As a detailed 504 
analysis of the phosphorylation state of SR proteins has not been addressed, we can only 505 
speculate that, similarly to what observed by Sacco-Bubulya P. et al [74], a reduced 506 
phosphorylation causes retention of SR proteins in nuclear spleckles. 507 
Finally, the decreased level of poly(A) signal in the cytoplasm of TF-silenced cells does not 508 
necessarily imply that poly(A) transcripts are improperly spliced and retained in the nucleus, as 509 
we could not see any visible increase of the nuclear signal. Thus the effect of TF silencing on 510 
mRNA biogenesis or on the mRNA export machinery [75] deserves further detailed 511 
investigations, however, it is not unlikely that splicing factors might alter the polyadenylation 512 
process as observed for PTB (reviewed in [76])  513 
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Nevertheless, the possibility that altered TF expression has an impact on overall splicing activity 514 
may help to explain its role in those diseases in which both TF and splicing activity are down-515 
regulated, and opens new avenues for the investigations of splicing regulation by TF. 516 
Although cardiomyopathies are only beginning to be explored in terms of splicing machinery, 517 
recent evidence suggests that RNA splicing is less efficient in humans with heart failure. Splicing 518 
changes have also been observed in hypertrophic myocardium with preserved systolic function, 519 
which suggests that they may occur before the onset of overt heart failure [77, 78]. 520 
It is worth noting that TF is down-regulated in the myocardium of patients with dilated 521 
cardiomyopathy [9], and that the deletion of the TF gene in mouse cardiomyocytes 522 
(TF
flox/flox/
MLC2v-Cre) leads to significantly increased fibrosis [79].  523 
The mechanisms underlying these phenomena have not been previously investigated, but our 524 
findings suggest that TF plays a role in controlling splicing machinery, although further studies 525 
are required to determine whether this mechanism is operative in cells other than cardiomyocytes.  526 
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FIGURE LEGENDS  542 
 543 
Figure 1. TF silencing reduced cell growth and induced apoptosis in HL-1 cardiomyocytes. 544 
A) TF mRNA analysed by qRT-PCR in control and TF siRNA-treated cells (n=10) *p<0.001 vs 545 
controls. B) BrdU incorporation assay of control and TF siRNA-treated cells (n=5) *p<0.01 vs 546 
controls. C) MTT assay of control and TF siRNA-treated cells (n=6) *p<0.01 vs controls. D) 547 
Apoptosis was determined by means of a nucleosome immunoassay. Mean values±SEM of seven 548 
independent experiments run in triplicate. *p<0.01 vs corresponding controls. Control: cells 549 
treated with a non-silencing oligonucleotide sequence; siTF: TF-silenced cells. 550 
 551 
Figure 2. Differentially expressed proteins in TF-silenced cells identified by LC-MS
E
. A) The 552 
data are expressed as the log(e) of the ratio of protein abundance in control and TF-silenced cells. 553 
The control cells’ unique protein value was set at -2, and that of the TF-silenced cells at +2. The 554 
data were obtained from three independent experiments performed in triplicate. B) Western blot 555 
and densitometric analyses of PTB, hnRNP A1, and hnRNP L. Mean values±SEM; *p<0.05 vs 556 
controls (n=3). Control: cells treated with a non-silencing oligonucleotide sequence; siTF: TF-557 
silenced cells. 558 
 559 
Figure 3. Differentially expressed proteins in TF-silenced cells identified by 2-DE. 560 
Representative images of 2-DE gels from control A) and TF-silenced B) cells. The spots showing 561 
significant differential expression are indicated by circles (1, hnRNP K; 2, HtrA2). 562 
Representative images of 2-DE spots of hnRNP K C) and HtrA2 D) in control and TF-silenced 563 
cells, and their respective densitometric analysis. Western blot and densitometric analyses of 564 
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hnRNP K E), and HtrA2 F). Mean values±SEM; *p<0.05 vs controls (n=3). Control: cells treated 565 
with a non-silencing oligonucleotide sequence; siTF: TF-silenced cells. 566 
 567 
Figure 4. Subcellular localisation of poly(A) RNA in TF-silenced cells. Poly(A) RNA 568 
localisation was visualised using a digoxigenin-labelled oligo-dT probe. The nucleus was stained 569 
with DAPI (shown in blue). The image is representative of four independent experiments (scale 570 
bar, 20 µm). Control: cells treated with a non-silencing oligonucleotide sequence; siTF: TF-571 
silenced cells. 572 
 573 
Figure 5. Subcellular localisation of SRSF2 in TF-silenced cells. SRSF2 was visualised using 574 
an anti-SRSF2 antibody. The nucleus was stained with DAPI (shown in blue). The image is 575 
representative of four independent experiments (scale bar, 10 µm). Control: cells treated with a 576 
non-silencing oligonucleotide sequence; siTF, TF-silenced cells. 577 
 578 
Figure 6. Pre-mRNA splicing assay in TF-silenced cells. The test system A) for in vivo splicing 579 
based on the reporter genes encoding β-galactosidase and luciferase, which were fused in-frame 580 
via a recombinant fragment of adenovirus and human αs-tropomyosin genes. The recombinant 581 
fragment contains three in-frame translation stop signals (XXX) in the intronic region. β-582 
galactosidase is generated in the absence of splicing, whereas an active fusion of β-galactosidase 583 
and luciferase is generated after the splicing of the primary transcript (adapted from [19] ). B) 584 
The cells were transiently transfected with the reporter construct (pTN24) and the splicing 585 
activator Tra2-α plasmid. The graph shows the percentage stimulation of splicing derived from 586 
the luciferase/β-galactosidase ratio. Mean values±SEM (n=7). *p<0.05 vs controls; #p<0.05 vs 587 
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controls transfected with pTN24 alone. Control: cells treated with a non-silencing oligonucleotide 588 
sequence; siTF: TF-silenced cells. 589 
 590 
Figure 7. Effect of TF silencing on regulators of apoptosis. A) Immunoblotting of 591 
phosphorylated Akt in TF-silenced and control cardiomyocytic cells. B) Immunoblotting of 592 
HtrA2 expression in cardiomyocytic cells treated with LY 294002 for four hours. C) MTT assay 593 
in cardiomyocytic cells treated with LY 294002 for four hours. D-F) RT-PCR analysis of Bcl-x, 594 
Survivin, and TRAIL in TF-silenced MDA-MB-231 cells. The densitometric analysis was made 595 
using QuantityOne software (v 4.5.2, Bio-Rad Laboratories). GAPDH mRNA was used for 596 
sample normalisation. The images are representative of three individual experiments. *p <0.01 vs 597 
controls (n=3). Control: cells treated with a non-silencing oligonucleotide sequence; siTF: TF-598 
silenced cells; - : vehicle-treated cells. 599 
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Table 1. Differentially expressed proteins in TF-silenced and control cells identified by LC–MSE. 600 
The data were obtained from three independent experiments performed in triplicate.  601 
 602 
Accession
a
 Description PLGS
Score 
Si-:SiTF
b
 
Log(e)Ratio 
Si-:SiTF 
Log(e)StdDev 
P 
value 
CV
c
 
       
Q8K310 Matrin-3  158.1 0.52 0.16 1 14.8% 
Q64012 RNA-binding protein 
Raly 
99 0.39 0.17 1 17.7% 
Q8R081 Heterogeneous nuclear 
ribonucleoprotein L  
225.5 0.27 0.06 1 9.1% 
Q60668 Heterogeneous nuclear 
ribonucleoprotein D0 
204 0.24 0.1 1 1.2% 
Q501J6 Probable ATP-
dependent RNA helicase 
DDX17  
337.5 0.24 0.09 1 2.3% 
Q8VIJ6 Splicing factor, proline- 
and glutamine-rich, PTB 
227.2 0.23 0.11 1 5.5% 
Q9Z1N5 Spliceosome RNA 
helicase Bat1, UAP56  
218.4 0.21 0.08 1 10.3% 
P62631 Elongation factor 1-
alpha 2  
309.6 0.19 0.08 1 4.1% 
Q8VDW0 ATP-dependent RNA 
helicase DDX39 
167.7 0.19 0.1 1 6.6% 
Q9DBG6 Dolichyl-diphospho-
oligosaccharide--protein 
glycosyltransferase 63 
kDa subunit precursor  
252.1 -0.21 0.11 0.02 7.0% 
P99024 Tubulin beta-5 chain  450.3 -0.23 0.07 0 17.1% 
Q01853 Transitional 
endoplasmic reticulum 
ATPase (TER ATPase)  
432.0 -0.23 0.1 0 11.4% 
Q922F4 Tubulin beta-6 chain 254.5 -0.23 0.14 0 9.5% 
P68372 Tubulin beta-2C chain  352.5 -0.24 0.11 0 16.9% 
P58771 Tropomyosin-1 alpha 
chain  
277.1 -0.25 0.09 0 5.6% 
P47738 Aldehyde 
dehydrogenase, 
mitochondrial precursor  
321.5 -0.27 0.1 0 9.5% 
P17182 Alpha-enolase  210.5 -0.28 0.13 0 20.4% 
P05213 Tubulin alpha-2 chain  345 -0.34 0.09 0 20.2% 
P05214 Tubulin alpha-3/alpha-7 
chain  
230.1 -0.34 0.09 0 15.4% 
P68373 Tubulin alpha-6 chain  396.3 -0.34 0.1 0 18.3% 
P68369 Tubulin alpha-1 chain  419.4 -0.35 0.12 0 16.5% 
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P68368 Tubulin alpha-4 chain  131.3 -0.43 0.1 0 26.2% 
Q9JJZ2 Tubulin alpha-8 chain  182.6 -0.44 0.12 0 19.3% 
 
Control cells unique 
    
P49312 Heterogeneous nuclear 
ribonucleoprotein A1  
180.2 Control unique   
P63011 Ras-related protein Rab-
3A  
132.4 Control unique   
Q05920 Pyruvate carboxylase, 
mitochondrial precursor  
333.1 Control unique   
Q921M3 Splicing factor 3B 
subunit 3  
245.5 Control unique   
Q9QXY Tight junction protein 
ZO-3  
205.4 Control unique   
TF-silenced cells unique 
P17183 Gamma-enolase  127.3 TF-silenced unique   
P21550 Beta-enolase  116.7 TF-silenced unique   
Q9QVP4 Myosin regulatory light 
chain 2, atrial isoform 
64 TF-silenced unique   
P06151 L-lactate dehydrogenase 
A chain  
154.6 
TF-silenced unique 
 
 
Q9ES82 
 
Popeye domain-
containing protein 2  
 
85.8 
TF-silenced unique 
 
 
 
      
a
Accession code in UniProt
 
b
Si- refers to control cells treated with a non-silencing oligonucleotide sequence. SiTF refers to TF-
silenced cells. 
c
 CV , coefficient of variation of the ratios in the three biological replicates 603 
